Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Asenapine Maleate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Saphris-Generic (asenapine) is a USFDA approved atypical antipsychotic that acts as Serotonin 2a (5-HT2a) & D2 receptor antagonist which is indicated for the treatment of schizophrenia & bipolar I disorder.
Brand Name : Saphris-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 08, 2021
Lead Product(s) : Asenapine Maleate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Asenapine Maleate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Saphris-Generic (asenapine) is a USFDA approved atypical antipsychotic that acts as Serotonin 2a (5-HT2a) & D2 receptor antagonist which is indicated for the treatment of schizophrenia & bipolar I disorder.
Brand Name : Saphris-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 11, 2020
Lead Product(s) : Asenapine Maleate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Asenapine Maleate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SECUADO achieved the primary endpoint, demonstrating statistically significant improvement in Positive and Negative Syndrome Scale (PANSS) total score change from baseline to Week 6 compared to placebo.
Brand Name : Secuado
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 15, 2020
Lead Product(s) : Asenapine Maleate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Asenapine Maleate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The approved ANDA is therapeutically equivalent to the reference listed drug product, Saphris Sublingual Tablets, 5 mg and 10 mg, of Allergan. Asenapine is an atypical antipsychotic indicated for bipolar I disorder as adjunctive treatment to lithium or v...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 11, 2020
Lead Product(s) : Asenapine Maleate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Asenapine Maleate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Livzon Pharmaceutical Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : LTS grants to LIVZON and its Affiliates an exclusive royalty-bearing, sublicensable right and license to jointly develop with LTS the Asenapine TTS and commercialize the Asenapine TTS for the treatment of schizophrenia in China (including Hong Kong and M...
Brand Name : Asenapine TTS
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 06, 2020
Lead Product(s) : Asenapine Maleate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Livzon Pharmaceutical Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?